When Two Antidepressants Haven't Worked: What's Next

If you're reading this, there's a good chance you already know a particular kind of exhaustion. Not just the exhaustion of depression, but the exhaustion of trying to get better and hitting a wall over and over.

You took the first antidepressant your doctor prescribed. You waited the six to eight weeks they told you to wait. It didn't work, or the side effects were intolerable, or it helped a little but not enough. So you tried another. Maybe a third. Maybe you've lost count.

Each round had a window of hope and a quiet disappointment. Each round, you wondered whether the problem was the medication or whether the problem was you.

I want to address that second question directly: it isn't you.

If two or more antidepressants haven't given you adequate relief at appropriate doses for adequate durations, you likely meet the clinical criteria for treatment-resistant depression (TRD). And the reason those medications haven't worked has to do with the biology of your depression, not with how hard you've tried.

What treatment-resistant depression actually means

The formal definition is unromantic: depression that hasn't responded to at least two adequate trials of antidepressants from different classes, at appropriate doses, for sufficient duration (typically six to eight weeks each). What "adequate" means in practice is that the trial wasn't cut short by side effects in the first two weeks, that the dose got into the therapeutic range, and that you actually took the medication consistently.

By that definition, somewhere around a third of people with major depression are treatment-resistant. That's not a small population. That's millions of people. (If your depression is partly chronic-pain-driven rather than purely psychiatric, our ketamine for chronic pain post covers that overlap.)

The numbers from the STAR*D trial (one of the largest depression treatment studies ever conducted) tell a discouraging story about the standard playbook. Roughly 30% of people don't adequately respond to their first antidepressant. After two failed trials, the remission rate from a third standard antidepressant drops to about 13-14%. By the fourth medication, the response rate is in single digits.

What this tells us isn't that medications don't work. It's that for the subset of patients whose depression is treatment-resistant, swapping to another medication of similar class is a low-yield strategy. The next step that statistically makes sense is something with a different mechanism: not just a different brand.

Why standard antidepressants fall short for some patients

Most conventional antidepressants (SSRIs like sertraline, fluoxetine, escitalopram; SNRIs like venlafaxine, duloxetine; and related medications) work by adjusting serotonin and/or norepinephrine signaling. The hypothesis is that depression involves a deficit in monoamine neurotransmitter activity, and increasing availability helps. For a lot of patients, that's right.

For patients with treatment-resistant depression, that hypothesis appears to be incomplete. Research over the past two decades has pointed to other neurobiological factors: disruptions in glutamate signaling, reduced neuroplasticity, decreased synaptic density in regions like the prefrontal cortex and hippocampus, and overactivity in the default mode network (the brain network responsible for ruminative self-referential thinking).

These aren't things SSRIs directly address. They're a different aspect of depression's biology, and treating them effectively requires a different mechanism. Which is the case for ketamine.

How ketamine targets what other medications can't

Ketamine doesn't touch the monoamine system meaningfully. It works on glutamate, the brain's primary excitatory neurotransmitter, by blocking NMDA receptors. That blockade kicks off a downstream cascade: more glutamate release, AMPA receptor activation, BDNF (brain-derived neurotrophic factor) production, and a window of accelerated synaptic plasticity that lasts days.

The clinical translation: rather than slowly nudging neurotransmitter levels and waiting for the brain to adapt, ketamine creates a brief window in which the brain becomes unusually capable of forming new connections. Whatever you do during that window (therapy, sleep, sunlight, movement, the people you love) gets disproportionate traction.

There's also evidence that ketamine helps reduce the hyperactivity in the default mode network that drives the relentless self-referential thinking many TRD patients describe as the hardest part of being depressed. Some patients describe the post-session experience as "mental space I haven't had in years."

The published response rates for sublingual or IV ketamine in TRD populations are typically 60-70%. That's meaningfully higher than what a third or fourth conventional antidepressant trial offers.

Your evidence-based options after failed antidepressants

Ketamine isn't your only option. Let me lay out the main paths a thoughtful psychiatrist would consider, with honest tradeoffs.

Ketamine therapy (at-home, sublingual)

A physician prescribes sublingual ketamine, taken at home in structured sessions with a sober adult sitter present. Ongoing telemedicine supervision. Initial loading phase of 10 or more sessions over 4-8 weeks, then individualized maintenance.

Strength of evidence: strong; multiple trials and substantial clinical experience for TRD. Response rates 60-70%.

Speed: noticeable improvement often within hours to days of the first session.

Practical: no clinic travel, but requires sitter and appropriate home environment. Stricter screening than clinic-based programs because the in-room safety net is further away.

Cost: at Tovani Health, $349 for one month, $598 for two months ($299/month avg), or $996 for four months ($249/month avg). HSA/FSA-eligible. Not insurance-covered (off-label).

Esketamine (Spravato) nasal spray

The FDA-approved esketamine nasal spray. Administered in a certified clinic, with two hours of in-person monitoring after each dose. You can't drive on dose days.

Strength of evidence: FDA-approved for TRD based on pivotal clinical trials.

Speed: rapid, comparable to racemic ketamine.

Practical: twice-weekly clinic visits during loading, weekly then biweekly during maintenance. Significant time commitment. Requires a certified center within reasonable distance.

Cost: insurance often covers with prior authorization for TRD, but copays vary widely; out-of-pocket without insurance is $25,000-$40,000/year given the drug acquisition cost plus monitoring fees.

Transcranial magnetic stimulation (TMS)

Non-invasive magnetic stimulation of the prefrontal cortex through a coil placed against your scalp. No medication, no sedation, fully alert during the procedure.

Strength of evidence: FDA-cleared for TRD since 2008, with response rates 50-60%.

Speed: typically four to six weeks before you know if it's working; gains tend to be durable after a completed course.

Practical: daily weekday clinic visits for four to six weeks (20-36 sessions). Each visit ~1 hour door-to-door. You can drive yourself. No sitter required.

Cost: insurance often covers with documented antidepressant failures; out-of-pocket without insurance is typically $6,000-$12,000 for a full course.

Electroconvulsive therapy (ECT)

The treatment with the strongest evidence base for severe depression. Brief electrical current passed through the brain under general anesthesia to induce a controlled seizure.

Strength of evidence: the highest of any TRD treatment. Response rates 50-70%, often higher in severe or psychotic depression.

Speed: improvement within one to two weeks for many patients.

Practical: requires anesthesia, hospital or surgical-center setting, 2-3 sessions per week for 3-4 weeks. Real risks including transient memory effects that some patients find distressing.

Cost: typically insurance-covered. The barriers are logistical and the side effect profile, not money.

Augmentation strategies

Adding a second medication to your existing antidepressant (most commonly an atypical antipsychotic like aripiprazole or lithium) to boost the SSRI's effect.

Strength of evidence: moderate. Useful for some patients, but response rates after multiple prior failures are modest. (For specific demographic considerations, see our posts on perimenopause and menopause depression, seniors over 60, and healthcare workers.)

Speed: weeks, similar to SSRI timeline.

Practical: usually the first thing your psychiatrist will try. More medications, more side effects, more waiting. Worth doing before more invasive options if you haven't yet.

How most patients I see end up choosing

When I lay these options out, the calculus most patients work through tends to weight a few things heavily.

Speed. After months or years of waiting for medications to do something, the idea of feeling different within days rather than weeks is compelling. This favors ketamine and ECT over TMS and augmentation.

Convenience and time. Spravato, TMS, and ECT all require multiple weekly clinic visits during loading. For people whose work or life can't absorb that, those options are functionally inaccessible regardless of clinical merit. At-home ketamine wins on this dimension.

Insurance coverage. Spravato, TMS, and ECT have realistic paths to insurance coverage. At-home ketamine and most clinic IV ketamine don't. If insurance changes the cash math, that should weigh.

Side effect tolerance. ECT's memory effects, antipsychotic augmentation's metabolic effects, SSRI augmentation's daily side effects: these are real and matter. Ketamine's side effects are confined to the session itself.

Whether you can stay on your current medication. In most cases you can continue your current antidepressant while starting ketamine; the mechanisms are different and don't conflict. This means no abrupt withdrawal during a vulnerable period. ECT and TMS likewise are usually layered on top of existing medications.

What I want you to know

The medications you tried weren't the wrong call when your psychiatrist prescribed them; they were the reasonable first steps. The fact that they didn't get you all the way back doesn't mean the system failed or that you're untreatable. It means your depression has a biology that those medications don't fully address, and the next reasonable step is something different in mechanism.

I see a lot of patients who arrive having internalized the disappointments of multiple failed trials as evidence that nothing will work for them. That belief is part of the depression talking. The data doesn't support it. After two failed antidepressants, several evidence-based options exist with meaningfully better odds than a third SSRI.

Frequently Asked Questions

When is depression considered "treatment-resistant"?

The standard clinical definition: failure to achieve adequate response after at least two antidepressants from different classes (e.g., an SSRI followed by an SNRI), each at therapeutic dose for 6-8 weeks. By that definition, roughly one-third of people with major depressive disorder are treatment-resistant. The term doesn't mean depression is permanent or untreatable; it means the standard first-line approach hasn't worked, and the next-line options (which include ketamine) are different in mechanism and often more effective.

How does ketamine compare to Spravato, TMS, and ECT?

Ketamine (racemic, off-label, often sublingual at home): 60-70% response rate in TRD, response within hours, ~$400-500/month. Spravato (esketamine nasal spray): similar efficacy, FDA-approved, partial insurance coverage but requires REMS-certified clinic visits twice weekly. TMS (transcranial magnetic stimulation): non-medication, 30-40 daily clinic visits over 6-8 weeks, response rate around 40-50% in TRD, well-tolerated. ECT (electroconvulsive therapy): highest response rate (60-80%), particularly for severe or psychotic depression, but requires general anesthesia and carries cognitive trade-offs.

Should I try a third or fourth antidepressant before ketamine?

Probably not, in most cases. After two adequate antidepressant trials have failed, response rates to a third or fourth medication drop to roughly 10-20%. By contrast, response rates to ketamine in this same TRD population run 60-70%. The mathematical case for trying a fundamentally different mechanism (NMDA antagonism via ketamine) before yet another serotonin-targeted drug is strong. That said, augmentation with lithium or an atypical antipsychotic is reasonable to consider in parallel, particularly if you've responded partially to your current medication.

Will I need to stop my current antidepressants to start ketamine?

No, in nearly all cases. Standard SSRIs, SNRIs, atypicals, and most augmenting agents are compatible with ketamine therapy and don't require a taper. The exceptions: MAOIs (phenelzine, tranylcypromine, selegiline) require a washout period before ketamine; tramadol (technically an analgesic with serotonergic activity) is also a flag. Continuing your current antidepressant during ketamine treatment is often preferable to stopping it; abrupt SSRI discontinuation can cause withdrawal symptoms that confuse the picture during early ketamine response.

Ready to find out if at-home ketamine is the right next step?

If you want to explore whether at-home ketamine fits your situation, here's the entry point. It takes about five minutes, and the answer is honest: sometimes "yes, let's evaluate," and sometimes "no, here's why, and here's what might serve you better."

• Eligibility check: tovanihealth.com/eligibility (5 minutes, FL and NJ residents)
• Phone: 561-468-6981
• What you get back: an honest answer including which next-step option might fit best if ketamine isn't yours.

Benjamin Soffer, DO — Tovani Health

Either way, you have options. The exhaustion of cycling through antidepressants doesn't mean the road ends there.

Related reading: treatment-resistant depression explained, ketamine vs. TMS, ketamine vs. Spravato, what if ketamine doesn't work.